Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
OpenAI Restricts Astra AI Over Cyberattack Risks 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
(4) - EconoTimes)
BERKELEY, Calif., March 01, 2018 -- Dynavax Technologies Corporation (NASDAQ:DVAX) today announced that on March 1, 2018 the Compensation Committee of Dynavax’s Board of Directors approved the grant of inducement stock options to purchase an aggregate of 30,000 shares of common stock to six new employees. These awards were granted pursuant to the Dynavax Technologies Corporation Inducement Plan, as an inducement material to the new employees entering into employment with Dynavax, in accordance with the NASDAQ Listing Rule 5635(c)(4).
Dynavax granted stock options to purchase shares of Dynavax’s common stock to the new employees with an exercise price of $16.05 per share, the closing price of Dynavax’s common stock on March 1, 2018, the effective date of such grants. The stock options awarded vest over a three-year period, with one-third of the shares subject to such awards vesting on the first anniversary of the award’s vesting commencement date, and 1/36th of the shares subject to such awards vesting monthly thereafter, subject to each such employee’s continued employment with Dynavax on such vesting dates.
Dynavax is providing this information in accordance with NASDAQ Listing Rule 5635(c)(4).
About Dynavax
Dynavax is a fully-integrated biopharmaceutical company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax discovers and develops novel vaccines and immuno-oncology therapeutics. The Company’s first commercial product, HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the United States. Dynavax's lead immunotherapy product, SD-101, is an investigational cancer immunotherapeutic currently being evaluated in Phase 1/2 studies and its second cancer immunotherapeutic, DV281, is in Phase 1 development. For more information, visit www.dynavax.com.
Contact:
David Burke
Director, IR & Corporate Communications
510.665.7269
[email protected]
